Post
Pharma’s engagement with healthcare providers has slipped in recent years
In recent years there has been a downward trend in health care provider (HCP) contact in the pharmaceutical industry with …
Madrigal ramps up preparations for commercial launch of resmetirom in NASH
Following the US Food and Drug Administration's (FDA) acceptance of Madrigal Pharmaceuticals' new drug application and priority review for …
BioVie reports protocol deviations in Phase III Alzheimer’s trial
Clinical-stage biotech BioVie has seen its Phase III Alzheimer’s disease (AD) study impeded by Good Clinical Practice (GCP) violations and …
BiVACOR wins IDE to start first-in-human study for artificial heart
The US Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) to BiVACOR’s total artificial heart (BTAH), …
CTO Europe 2023: Fostering diverse oncology trials remains a challenge
Lacking diversity in clinical trials remains a challenge as 73% of global study participants are white, based on data presented …
AbbVie’s Teliso-V succeeds across key NSCLC endpoints
Biopharma giant AbbVie has announced that pipeline candidate Teliso-V (telisotuzumab-vedotin) demonstrated a clinically meaningful overall response rate (ORR) in a …
Calliditas starts Phase II trial for rare kidney disease therapy
Calliditas Therapeutics has initiated a Phase II trial to evaluate setanaxib as a treatment for Alport syndrome. The randomised, placebo-controlled Phase …
4Moving Biotech shares innovative trial plans for GLP-1 osteoarthritis drug
After recently completing the recruitment for its Phase I trial, 4Moving Biotech is already laying out plans for the upcoming …
AML cell therapy trials to watch in 2024 targeting GvHD
Patients with Acute Myeloid Leukemia (AML) can sit on waiting list for months on end for a donor. After the …
Health Canada approves third stage of ProJenX’s ALS trial
US-based clinical-stage biotech ProJenX has been given authorisation by Health Canada to launch the final part of its Phase I …
New study challenges current age-based colorectal cancer screening guidelines
Colorectal cancer (CRC) is responsible for more than 50,000 deaths per year and is the third most fatal type of …
Candel downsizes to focus on oncolytic virus-based cancer therapies
Candel Therapeutics has fired approximately 50% of its workforce in an effort to extend its cash runway into Q4 FY …
CTO Europe 2023: Reflections on drug development through the phases
Precision medicine oncology trial designs improve the likelihood of a drug’s approval by 38%, based on a presentation held by …
How to manage temperature-controlled shipments in unpredictable climate zones
Drugs have very specific temperature and storage requirements that must be considered at every point in the supply chain. Temperatures …
Arrowhead seeks regulatory clearance for Type 1 myotonic dystrophy trial
Arrowhead Pharmaceuticals has submitted an application seeking regulatory clearance to commence a Phase I/IIa clinical trial of its investigational RNA interference (RNAi) …